Contact
Social
Category
Primary
pharmaceutical-drugs · embed-ft 0.79
Tree path
Medical Health › Pharmaceutical Drugs
Group (tier-1)
Tech stack
AI readiness
Compliance (GEO / GDPR)
TLD
Overview
Title
EGFR+ mNSCLC Treatment | RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) HCP
Description
The official healthcare provider website for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and RYBREVANT® (amivantamab-vmjw), treatments for EGFR+ mNSCLC. See full Prescribing & Safety Information.
Final URL
Language
en (html)
Scanned at
2026-06-27 14:57:32